bpc-157 reduces fibrosis scarring Targeted immunotherapy rescues pulmonary by reducing activated fibroblasts and regulating alveolar cell profile Peptide Therapy 101: Can BPC-157

Current evidence underscores the necessity of further scientific assessment, more precise regulatory definitions, and robust banned-substance detection strategies to ensure safe use among athletes, tactical professionals, and the general public

While it shows potential for promoting tissue repair and reducing inflammation, its premature to label it a cure for chronic conditions without more robust clinical data

Its dual-receptor agonism and extended activity profile position it as a promising candidate for further investigation in weight regulation models

Brains were fixed, cryoprotected, and sectioned for immunofluorescent labeling using anti-Fos antibodies and fluorescent secondary antibodies